Reported 0 shares, down 1,680,000 (100.0%) from the prior quarter.
Reported value -100.0%; share count -100.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
|
This position's reported history falls outside the five-year preview window. A free account unlocks it.
Unlock full history
|
|||||||
Who else reported the position
42 managers reported BIOMARIN PHARMACEUTICAL INC for Q1 2017.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| ADVENT CAPITAL MANAGEMENT DE | Added | 64,770,000 | +8,703,000 | 1.38% | $73,667,000 | 14 qtrs |
| Allianz Asset Management GmbH | Unchanged | 41,080,000 | 0 | 0.05% | $46,624,000 | 8 qtrs |
| Calamos Advisors LLC | Reduced | 38,745 | -343 | 0.35% | $43,974,000 | 14 qtrs |
| MACKAY SHIELDS LLC | Reduced | 38,633,000 | -43,000 | 1.99% | $43,803,000 | 14 qtrs |
| OAKTREE CAPITAL MANAGEMENT LP | Reduced | 32,163,000 | -3,860,000 | 0.53% | $36,696,000 | 5 qtrs |
| PFM Health Sciences LP | Reduced | 29,934,000 | -438,000 | 0.85% | $33,956,000 | 3 qtrs |
| JPMorgan Chase & Co | Reduced | 15,294,000 | -1,828,000 | < 0.01% | $17,333,000 | 14 qtrs |
| BAKER BROS ADVISORS LP | Unchanged | 12,228,000 | 0 | 0.11% | $13,830,000 | 14 qtrs |
| CREDIT SUISSE AG | Reduced | 11,574,000 | -301,000 | 0.01% | $13,072,000 | 14 qtrs |
| Invesco Ltd | Unchanged | 8,517,000 | 0 | < 0.01% | $9,619,000 | 14 qtrs |
Filing details and methodology As reported
- Report period
- March 31, 2017
- Filed
- May 15, 2017
- Filing type
- 13F-HR
- Position type
- CB
Voting authority reported
No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.